ARE THERE ANY DIFFERENCES IN RESISTANCE MUTATIONS IN HIV-1 INFECTED NON B SUBTYPES FAILING THERAPY?
: A SYSTEMATIC REVIEW OF EVIDENCE (1986-2007) JL Martinez-Cajas, N Pant-Pai, MA Wainberg, MB Klein Montréal, QC Objective: Ninety percent of HIV-1 infected people worldwide harbor variants of HIV-1 non-B subtype. Knowledge of resistance mutations in non-B subtype HIV-1 and their clinical relevance is limited. We aimed to characterize antiretroviral (ARV) resistance mutations emerging in non-B subtype HIV-1 isolates reported to date. Methods: We conducted a systematic review (1986-2007) of studies that performed genotyping of isolates from treated (or naïve and treated) non-B subtype HIV-1 infected patients. Two reviewers searched 11 databases and retrieved 3486 citations in all areas of non-B subtype-related research. Forty five studies reporting genotyping data from non-B subtypes clinical isolates exposed to reverse transcriptase inhibitors and/or protease inhibitors (PI) were included. Two groups were analyzed: ART-treated patients (n=36) and prevention of vertical transmission with
